IRIS
SPAGNOLO, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 7.276
AS - Asia 26
NA - Nord America 6
SA - Sud America 4
Totale 7.312
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 7.276
CN - Cina 16
SG - Singapore 9
US - Stati Uniti d'America 5
AR - Argentina 2
CO - Colombia 1
DO - Repubblica Dominicana 1
EC - Ecuador 1
JP - Giappone 1
Totale 7.312
Salva come PNG Salva come JPEG
Città #
Genoa 3.937
Genova 1.898
Vado Ligure 905
Rapallo 512
Bordighera 22
Beijing 9
Singapore 7
Ashburn 5
Turin 2
Bogotá 1
Buenos Aires 1
Portoviejo 1
Santiago del Estero 1
Santo Domingo 1
Tokyo 1
Totale 7.303
Salva come PNG Salva come JPEG
Nome #
Guidelines for the diagnosis and treatment of basal cell carcinoma: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology 287
Heterogeneity and frequency of BRAF mutations in primary melanoma: Comparison between molecular methods and immunohistochemistry 214
Analisi fenotipica e funzionale dell’infiltrato linfocitario in biopsie di metastasi di melanoma, in pazienti in terapia con farmaci a bersaglio molecolare e/o inibitori dei checkpoint immunologici 192
CDKN2A germline mutations are not associated with poor survival in an Italian cohort of melanoma patients 184
Cytokines can counteract the inhibitory effect of MEK-i on NK-cell function 184
BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies. 183
Combining molecular and immunohistochemical analyses of key drivers in primary melanomas: Interplay between germline and somatic variations 179
Ataxia-Telangiectasia Mutated Loss of Heterozygosity in Melanoma 177
BRAF plus MEK-targeted drugs: a new standard of treatment for BRAF-mutant advanced melanoma 173
Italian survey on managing immune checkpoint inhibitors in oncology during COVID-19 outbreak 173
Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup 168
Functional characterization of a multi-cancer risk locus on chr5p15.33 reveals regulation of TERT by ZNF148 156
HO-1 downregulation favors BRAFV600 melanoma cell death induced by Vemurafenib/PLX4032 and increases NK recognition 147
Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma. 139
CTLA-4 gene variant -1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab 133
Regenerative surgery for the definitive surgical repair of enterocutaneous fistula 131
Clinical, pathological and dermoscopic phenotype of MITF p.E318K carrier cutaneous melanoma patients 131
Correction: Combining molecular and immunohistochemical analyses of key drivers in primary melanomas: Interplay between germline and somatic variations [Oncotarget. 2018; 9:5691-5702]doi 10.18632/oncotarget.23204 127
Regenerative surgery for the definitive repair of a vasculitic nonhealing ulcer using platelet-derived growth factors and noncultured autologous cell suspension 123
Solar radiation as a risk factor for cutaneous melanoma: Review 119
Diagnosis of lung cancer following emergency admission: Examining care pathways, clinical outcomes, and advanced NSCLC treatment in an Italian cancer Center 117
Insights into genetic susceptibility to melanoma by gene panel testing: Potential pathogenic variants in acd, atm, bap1, and pot1 110
Response to ipilimumab therapy in metastatic melanoma patients: potential relevance of CTLA-4+ tumor infiltrating lymphocytes and their in situ localization 110
Phenotypic characterization of tumor CTLA-4 expression in melanoma tissues and its possible role in clinical response to Ipilimumab 109
Regenerative surgery for the definitive repair of chronic ulcers: a series of 34 cases treated with platelet-derived growth factors. 108
Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort 107
Current State of Target Treatment in BRAF Mutated Melanoma 104
Survival of patients with metastatic melanoma and brain metastases in the era of MAP-kinase inhibitors and immunologic checkpoint blockade antibodies: A systematic review 101
Regenerative Medicine for the Treatment of Teno-desmic Injuries of the Equine. A Series of 150 Horses Treated with Platelet-derived Growth Factors 100
The Use of Platelet-rich Plasma Gel in Patients with Mixed Tumour Undergoing Superficial Parotidectomy: A Randomized Study 97
Case Report: Immune-Related Toxicity During Adjuvant Treatment With BRAF Plus MEK Inhibitors in a Melanoma Patient 89
Efficacy of braf and mek inhibition in patients with braf‐mutant advanced melanoma and germline cdkn2a pathogenic variants 86
Activity and safety of first-line treatments for advanced melanoma: A network meta-analysis 84
Association of vacuum-assisted closure and platelet gel for the definitive surgical repair of an enterocutaneous fistula: a case report. 83
Front-line liquid biopsy for early molecular assessment and treatment of hospitalized lung cancer patients 80
How to make immunotherapy an effective therapeutic choice for uveal melanoma 80
Neuromuscular and cardiac adverse events associated with immune checkpoint inhibitors: pooled analysis of individual cases from multiple institutions and literature 74
The treatment of melanoma brain metastases before the advent of targeted therapies: associations between therapeutic choice, clinical symptoms and outcome with survival 70
Cerivastatin Synergizes with Trametinib and Enhances Its Efficacy in the Therapy of Uveal Melanoma 68
Immunotherapy in Adolescents and Young Adults: What Remains in Cancer Survivors? 68
The Current State of Molecular Testing in the BRAF-Mutated Melanoma Landscape 67
Non-BRAF Mutant Melanoma: Molecular Features and Therapeutical Implications 67
The treatment of advanced melanoma: Current approaches and new challenges 64
Development of a gene panel for hotspot mutation and copy number alterations based uveal melanoma prognostication. 59
Primary endobronchial melanoma: a case report and clinical management indications 58
Whole-Exome Sequencing and cfDNA Analysis Uncover Genetic Determinants of Melanoma Therapy Response in a Real-World Setting 56
Association between PD-1 single nucleotide gene variants and the risk of metastatic melanoma 55
Predictors of germline status for hereditary melanoma: 5 years of multi-gene panel testing within the Italian Melanoma Intergroup 55
Interdependence of Molecular Lesions That Drive Uveal Melanoma Metastasis 54
Molecular Assessment in Patients with Melanoma: When and Why? 54
Hedgehog Inhibitors beyond Clinical Complete Response in Basal Cell Carcinoma: Should i Stop or Should i Go? 53
Neoadjuvant treatments in patients with high-risk resectable stage III/IV melanoma 48
Combined robotic inguinal and iliac-obturator lymphadenectomy for stage III skin cancers: Surgical technique and preliminary results 45
Merkel Cell Carcinoma: An Immunotherapy Fairy-Tale? 45
How I perform fertility preservation in breast cancer patients 45
Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer 44
Treatment beyond progression with anti-PD-1/PD-L1 based regimens in advanced solid tumors: a systematic review 44
Early discontinuation of cemiplimab in patients with advanced cutaneous squamous cell carcinoma 44
Assessing Determinants of Response to PARP Inhibition in Germline ATM Mutant Melanoma 44
Anastrozole-Induced Carpal Tunnel Syndrome: Results From the International Breast Cancer Intervention Study II Prevention Trial 42
Safety of fertility preservation techniques before and after anticancer treatments in young women with breast cancer: a systematic review and meta-analysis 41
Immune-checkpoint inhibitors for the treatment of metastatic melanoma: a model of cancer immunotherapy 40
Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study 40
Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study 39
Immunotherapy for the Treatment of Cutaneous Squamous Cell Carcinoma 38
ADAM10 correlates with uveal melanoma metastasis and promotes in vitro invasion 37
The predictive and prognostic role of single nucleotide gene variants of PD-1 and PD-L1 in patients with advanced melanoma treated with PD-1 inhibitors 37
Safety of Extended interval Dosing Immune Checkpoint Inhibitors: a multicentre cohort study 36
Guidelines for the diagnosis and treatment of cutaneous squamous cell carcinoma: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology 36
Association of CTLA-4 gene variants with response to therapy and long-term survival in metastatic melanoma patients treated with ipilimumab: An Italian melanoma intergroup study 36
Nationwide multidisciplinary consensus on the clinical management of Merkel cell carcinoma: a Delphi panel 35
Machine Learning Methods for Gene Selection in Uveal Melanoma 34
Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab 34
Current status and perspectives in immunotherapy for metastatic melanoma 33
Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma 33
Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma 33
mAbs targeting CTLA-4 and clinical outcomes 32
Update on Metastatic Uveal Melanoma: Progress and Challenges 31
The adjuvant treatment revolution for high-risk melanoma patients 30
Sun exposure and melanoma prognostic factors 29
Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study 29
No impact of NRAS mutation on features of primary and metastatic melanoma or on outcomes of checkpoint inhibitor immunotherapy: An italian melanoma intergroup (IMI) study 29
Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index 27
Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice 27
Binimetinib for the treatment of NRAS-mutant melanoma 27
Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases 26
Treatment of metastatic uveal melanoma with intravenous fotemustine 26
Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study 26
Basal and one-month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma 24
Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme 24
Uveal melanoma 24
Atypical responses in patients with advanced melanoma, lung cancer, renal-cell carcinoma and other solid tumors treated with anti-PD-1 drugs: A systematic review 24
Characteristics of Real-World Patients with High-Risk BRAFV600E/K-Mutated Melanoma Receiving Adjuvant Treatment with Dabrafenib Plus Trametinib After Surgical Resection, Through the Italian Managed Access Program 23
Upcoming strategies for the treatment of metastatic melanoma 23
Management of immune-related adverse events during treatment with immune checkpoint inhibitors 23
Uveal melanoma 22
Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy 22
Combined vemurafenib and fotemustine in patients with BRAFV600 melanoma progressing on vemurafenib 22
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial 18
Effect of age on melanoma risk, prognosis and treatment response 18
Totale 7.396
Salva come PNG Salva come JPEG
Categoria #
all - tutte 30.082
article - articoli 28.750
book - libri 0
conference - conferenze 189
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 665
Totale 59.686
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021284 0 0 0 46 31 14 27 35 31 48 35 17
2021/2022434 21 21 23 46 21 42 19 81 38 61 13 48
2022/2023620 49 52 6 53 112 93 4 48 89 8 98 8
2023/2024600 12 42 18 81 34 80 21 56 30 29 36 161
2024/20252.620 107 168 53 143 301 250 197 379 104 110 262 546
2025/20261.733 508 195 661 369 0 0 0 0 0 0 0 0
Totale 7.578